NOVOGEN LIMITED ABN 37 063 259 754Novogen LTD • October 25th, 2017 • Pharmaceutical preparations
INDICATES CONFIDENTIAL MATERIAL OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION SEPARATELY WITH A REQUEST FOR CONFIDENTIAL TREATMENT.Novogen LTD • October 25th, 2017 • Pharmaceutical preparations • Australian Capital Territory
A This Agreement is made pursuant to the projects stream of the Programme. The objective of the projects stream is to support industry-identified and industry-led collaborative research to develop products, services or processes that will solve industry problems and deliver tangible outcomes.
INDICATES CONFIDENTIAL MATERIAL OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION SEPARATELY WITH A REQUEST FOR CONFIDENTIAL TREATMENT.Novogen LTD • October 25th, 2017 • Pharmaceutical preparations • New South Wales
Capital Raising Value means, with respect to each Capital Raising, the aggregate value of funds actually received for all new Securities in the Buyer received in that Capital Raising. The following will not be considered in determining the value of any Capital Raising:
EMPLOYMENT AGREEMENTEmployment Agreement • October 25th, 2017 • Novogen LTD • Pharmaceutical preparations • Massachusetts
This Executive Employment Agreement (“Agreement”) dated as of September 1, 2016 (the “Effective Date”), is between Novogen North America, Inc., (the “Company”) and Dr. Peng Leong (“Executive”).
NOVOGEN LIMITED ABN 37 063 259 754Novogen LTD • October 25th, 2017 • Pharmaceutical preparations
INDICATES CONFIDENTIAL MATERIAL OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION SEPARATELY WITH A REQUEST FOR CONFIDENTIAL TREATMENT. EXCLUSIVE LICENSE AGREEMENT BETWEEN GENENTECH, INC....Exclusive License Agreement • October 25th, 2017 • Novogen LTD • Pharmaceutical preparations • California
This Exclusive License Agreement (“Agreement”) is made and entered into as of the 25th day of October, 2016 (the “Effective Date”) by and between Novogen Limited, ACN 063 259 754, a corporation with a principal place of business at Suite 502, Level 5, 20 George Street, Hornsby, NSW 2077, Australia (“Novogen”) and Genentech, Inc., a Delaware corporation, with offices located at 1 DNA Way, South San Francisco, CA 94080 (“Genentech”). Novogen and Genentech are each referred to herein individually as a “Party” and collectively as the “Parties.”
